Erectile Dysfunction Clinical Trial
Official title:
The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Verified date | August 2018 |
Source | Pusan National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: KBMSI-2, which is the herbal formular consisted of Ginseng Radix Rubra, Dioscorea
tenuipes, Cornus officinalis Sieb. Et Zucc, Lycium Chinese Mill, Curcuma logna Linn, Honey,
improved the erectile function by preserving the smooth muscle content and inhibiting the
fibrosis of the corpus cavernosum in STZ-induced diabetic rat model. In this study, the
researchers investigated the efficacy and safety of the herbal formula (KBMSI-2) in the
treatment of ED.
Material and Methods: Patients were instructed to take investigational products (KBMSI-2 6g
or placebo) twice a day for 8 weeks at least 1 hour after food intake. The primary efficacy
variable was the change in the EF domain scores of the IIEF questionnaire from baseline.
Secondary efficacy measures included change in all domain scores of the IIEF from baseline,
change in question 2 and 3 of the SEP2,3, from baseline.
Status | Completed |
Enrollment | 44 |
Est. completion date | January 3, 2013 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 19 Years to 40 Years |
Eligibility |
Inclusion criteria were as follows: - men with history of ED for at least 6 months according to the National Institutes of Health (NIH) Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance); - erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire = 25; - age range between 19 and 40 years old; - patients were required to be involved in a stable, monogamous relationship with a female sexual partner and having failed >50% of at least four sexual attempts during the run-in period. Exclusion criteria were as follows: - Men with the following conditions were excluded from the study: - penile anatomical defects, - spinal cord injury, - radical prostatectomy, - and radical pelvic surgery; - a primary diagnosis of another sexual disorder; - uncontrolled DM (HBA1C> 12%); - serum creatinine>2.5mg/dL; - major uncontrolled psychiatric disorder; - history of major hematological, renal, or hepatic abnormalities; - recent (within the previous 6 months) history of cardiovascular disease, stroke or myocardial infarction, cardiac failure, unstable angina, life-threatening arrhythmia and a history of alcoholism or substance abuse. - Patients having taken PDE5 inhibitors and testosterone replacement therapy within 2 weeks were excluded in the study. Concomitant use of ED treatment was forbidden. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Department of Urology, Pusan National University Hospital | Busan |
Lead Sponsor | Collaborator |
---|---|
Hyun Jun Park |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the EF domain scores of the IIEF questionnaire from baseline | calculated by comparing total scores from questions 1 to 5 and 15 from IIEF questionnaire | Baseline, 4weeks, 8weeks | |
Secondary | Change in all domain scores of the IIEF from baseline | Baseline, 4weeks, 8weeks | ||
Secondary | change in question 2 and 3 of the Sexual Encounter Profile (SEP2: Were you able to insert your penis in your partner's vagina? SEP3: Did your erection last long enough for you to have a successful intercourse?) from baseline | change in question 2 and 3 of the Sexual Encounter Profile (SEP2: Were you able to insert your penis in your partner's vagina? SEP3: Did your erection last long enough for you to have a successful intercourse?) from baseline | Baseline, 4weeks, 8weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |